Tarsus Pharmaceuticals, Inc. (TARS) Q4 2025 Earnings Call Transcript

Tarsus Pharmaceuticals, Inc. (TARS) Q4 2025 Earnings Call Transcript

Seeking Alpha • 13 hours ago

Tarsus Pharmaceuticals: Q4 Results Highlight Xdemvy Blockbuster Potential

Tarsus Pharmaceuticals remains a Strong Buy, driven by Xdemvy's robust growth and management's $2B+ peak sales target. FY 2025 revenue surged 150% to $451M, with 2026 guidance at $670–$700M and 93% gross margins, though profitability is now expected in 2027. Xdemvy's US market penetration is just 5.6%, with international launches in China (2026) and Europe (2027) set to drive further growth.

Seeking Alpha • 5 hours ago

Tarsus Pharmaceuticals, Inc. (TARS) Reports Q4 Loss, Beats Revenue Estimates

Tarsus Pharmaceuticals, Inc. (TARS) came out with a quarterly loss of $0.2 per share versus the Zacks Consensus Estimate of a loss of $0.19. This compares to a loss of $0.6 per share a year ago.

Zacks Investment Research • a day ago

Tarsus Pharmaceuticals Appoints Renowned Biopharmaceutical Leader and Former Allergan CEO, David Pyott, to its Board of Directors

IRVINE, Calif., Feb. 18, 2026 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS) today announced the appointment of David E. I. Pyott, a distinguished leader in the global biopharmaceutical industry and former Chairman and CEO of Allergan, Inc., to its Board of Directors.

GlobeNewsWire • Feb 18, 2026

Tarsus to Report Fourth Quarter and Full Year 2025 Financial Results on Monday, February 23, 2026

IRVINE, Calif., Feb. 17, 2026 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS), today announced that it will host a live webcast at 1:30 p.m. PT / 4:30 p.m. ET on Monday, February 23, 2026 to report its fourth quarter and full year 2025 financial results and provide a corporate update.

GlobeNewsWire • Feb 17, 2026

Tarsus Pharmaceuticals, Inc. (TARS) Expected to Beat Earnings Estimates: Can the Stock Move Higher?

Tarsus Pharmaceuticals (TARS) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zacks Investment Research • Feb 17, 2026

Allspring Emerging Growth Fund Q4 2025 Performance Review

After years of underinvestment and production delays across the aerospace industry, ATI is now capitalizing on a surge in demand fueled by Boeing and Airbus' historically large backlogs for new aircraft.

Seeking Alpha • Feb 4, 2026

Down 16.4% in 4 Weeks, Here's Why You Should You Buy the Dip in Tarsus Pharmaceuticals (TARS)

Tarsus Pharmaceuticals (TARS) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term.

Zacks Investment Research • Jan 26, 2026

BMRN or TARS: Which Is the Better Value Stock Right Now?

Investors interested in Medical - Biomedical and Genetics stocks are likely familiar with BioMarin Pharmaceutical (BMRN) and Tarsus Pharmaceuticals, Inc. (TARS). But which of these two stocks is more attractive to value investors?

Zacks Investment Research • Jan 13, 2026

Tarsus Pharmaceuticals: Xdemvy Momentum Continues In Q3

Tarsus Pharmaceuticals, Inc. is upgraded to Strong Buy with a 12-month price target of $100/share, driven by Xdemvy's rapid commercialization. Xdemvy remains the only approved treatment for Demodex blepharitis, with accelerating sales growth and significant untapped patient population in the U.S. TARS is poised for further upside from global expansion, robust pipeline, and an earnings inflection expected in 2026 as revenue growth achieves profitability.

Seeking Alpha • Nov 20, 2025